Last reviewed · How we verify
ATH-399A 10 mg
At a glance
| Generic name | ATH-399A 10 mg |
|---|---|
| Sponsor | HanAll BioPharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- COVID-19, conjunctivitis, asymptomatic bacteriuria, nasopharyngitis
- Nasal congestion, nasal dryness, oropharyngeal pain, hiccups
- Dry mouth, abdominal discomfort, constipation, abdominal pain
- Skin irritation
- Blood pressure decreased, blood pressure increased, blood creatine phosphokinase increased, electroc
- Accelerated idioventricular rhythm, ventricular tachycardia
- Abnormal sensation in eye, conjunctival hyperaemia
- Presyncope, headache
- Back pain, musculoskeletal chest pain, neck pain
- Fatigue
- Lip injury
- Insomnia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATH-399A 10 mg CI brief — competitive landscape report
- ATH-399A 10 mg updates RSS · CI watch RSS
- HanAll BioPharma Co., Ltd. portfolio CI